Malignant granular cell tumour is a very rare cancerous form of a usually benign nerve-sheath-related growth. It tends to be larger and grow faster than the benign kind. Wide surgical removal is the main treatment, and close follow-up is needed because it can spread.
What is a malignant granular cell tumour?
A malignant granular cell tumour is a very rare soft tissue cancer related to the Schwann cells, the cells that wrap around and protect nerves. Its cells are packed with tiny granules that make them look grainy under the microscope, which gives the tumour its name.
Granular cell tumours themselves are not unusual. They often appear as small, firm lumps in the skin, tongue, breast or other soft tissues, and the great majority are benign. Only a small proportion, usually estimated at 1-2%, are malignant. These malignant forms behave like a high-grade sarcoma, with a tendency to return locally and to spread to lymph nodes, lungs and bone (Fanburg-Smith et al., 1998).
Telling a malignant granular cell tumour from a benign one can be difficult. Pathologists use a set of microscope criteria, described in 1998, together with the size and behaviour of the tumour. In practice, spread to other organs remains the only certain proof of malignancy (Nasser et al., 2011).
The main treatment is wide surgical removal. Radiotherapy and drug treatments are used in some cases, but the tumour responds poorly to most chemotherapy. Outlook depends heavily on size and whether the tumour has spread.
1. Key facts at a glance
2. Types
The granular cell tumour spectrum
Fanburg-Smith and colleagues proposed six microscope criteria to separate benign, atypical and malignant tumours (Fanburg-Smith et al., 1998).
A simpler approach
A later study suggested that two features, necrosis and increased mitoses, could identify potentially aggressive tumours just as well as the six criteria. The proliferation marker Ki-67 may help in difficult cases (Nasser et al., 2011).
Granular cell tumours in different places
3. Causes and risk factors
The cause is not known.
4. How does it look
On examination
On scans
Under the microscope
In the original study of 73 tumours, almost all expressed S-100 protein, and a Ki-67 index above 10% was linked with poorer survival (Fanburg-Smith et al., 1998).
Why diagnosis is challenging
Granular cell tumours are usually benign and slow-growing, so a small biopsy may not show the features of malignancy, which can be patchy. Pathologists therefore prefer to examine the whole tumour after removal. Even then, some tumours sit in a grey zone: they look atypical but not clearly malignant. A Japanese study found that some atypical tumours did spread, so these patients need careful follow-up (Imanishi et al., 2016).
Doctors also look at the clinical picture. A large tumour, deep location, rapid growth or recurrence after removal raises concern, even if the microscope findings are borderline. Discussion at a sarcoma multidisciplinary meeting brings these pieces of information together.
5. Symptoms
Common symptoms
- A firm lump in the thigh, arm, trunk or another part of the body
- A lump that is growing
- Pain or tenderness in some cases
Less common symptoms
When to seek medical advice
See a doctor about any lump that is larger than 5 cm, deep, growing or painful, or a lump that returns after removal.
6. Diagnosis
Staging
Staging uses the TNM system for soft tissue sarcoma, considering size, depth, grade, nodal spread and distant spread. Unlike most sarcomas, malignant granular cell tumours spread to lymph nodes relatively often. In a Japanese multicentre study, several patients had lymph node spread at presentation (Imanishi et al., 2016).
7. Treatment
Treatment should be planned by a specialist sarcoma team.
Surgery
Even after wide excision, local recurrence can occur. In the Japanese study, three of ten patients treated with wide resection developed a local recurrence (Imanishi et al., 2016).
Radiotherapy
Drug treatment
In the Japanese series, some patients receiving chemotherapy had stable disease for a year or longer, but all patients with recurrence or spread eventually died of the disease (Imanishi et al., 2016).
Treatment by situation
Recovery after surgery
Side effects
8. Outlook (prognosis)
Factors affecting outlook
Registry data include tumours of all types and sites, which may explain why survival appears better than in pathology series focused on deep soft tissue tumours.
9. Follow-up
10. Living with a malignant granular cell tumour
- Ask for review in a specialist sarcoma centre
- Keep follow-up appointments, including chest scans
- Report new lumps, especially in the groin or armpit, without waiting for your next appointment
- Work with physiotherapists to restore movement after surgery
- Manage lymphoedema with compression and exercises if lymph nodes were removed
- Protect the treated skin from sun if you had radiotherapy
- Keep a record of your scans, results and treatment dates
- Seek support from sarcoma charities and support groups
Coping with a rare diagnosis
Being told you have a very rare cancer can feel isolating, and reliable information can be hard to find. Specialist sarcoma nurses can explain test results, coordinate appointments and point you to support. Some people find it helpful to connect with others through rare cancer networks or online communities run by recognised charities.
11. Frequently asked questions
12. Questions to ask your care team
- How many malignancy criteria did my tumour meet?
- What were the size, margins and Ki-67 results?
- Has the tumour spread to lymph nodes or elsewhere?
- Do I need radiotherapy?
- Is there any role for drug treatment or a clinical trial?
- How often will I have scans?
- Should my tumour be reviewed by a second pathologist?
- Who is my key contact in the sarcoma team?
Resources
- Fanburg-Smith, J.C. et al. (1998) ‘Malignant granular cell tumor of soft tissue: diagnostic criteria and clinicopathologic correlation’, American Journal of Surgical Pathology, 22(7), pp. 779-794.
- Imanishi, J. et al. (2016) ‘Atypical and malignant granular cell tumors in Japan: a Japanese Musculoskeletal Oncology Group (JMOG) study’, International Journal of Clinical Oncology, 21(4), pp. 808-816.
- Moten, A.S. et al. (2018) ‘Malignant granular cell tumor: clinical features and long-term survival’, Journal of Surgical Oncology, 118(6), pp. 891-897.
- Nasser, H. et al. (2011) ‘Malignant granular cell tumor: a look into the diagnostic criteria’, Pathology, Research and Practice, 207(3), pp. 164-168.
- National Cancer Institute (2026) Adult Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.